Group 1 - Company approved the use of up to RMB 2.5 billion of idle funds for cash management, including investments in fixed-income products and time deposits [1][2] - The cash management program allows for rolling use of funds within the approved limit, with the chairman authorized to implement related matters [1] - Recent cash management activities have resulted in the maturity and recovery of certain products [2] Group 2 - Company agreed to provide a guarantee for its wholly-owned subsidiary, Hainan Hongxiang Yixintang Pharmaceutical Chain Co., Ltd., to apply for a credit limit of RMB 1.408 billion from banks [5][6] - A maximum guarantee amount of RMB 30 million has been established under a joint liability guarantee contract with Shanghai Pudong Development Bank [7][8] - The total amount of guarantees provided by the company and its subsidiaries is RMB 1.34227 billion, with a current balance of RMB 900.898 million, representing 11.77% of the company's audited net assets for 2024 [9][10]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2026-005 号 一心堂药业集团股份有限公司 关于全资子公司海南鸿翔一心堂医药连锁有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司")于 2025 年 12 月 10 日召开 2025 年度第 四次临时股东会，审议通过《关于公司同意子公司 2026 年向相关银行申请综合授信额度并为其 提供担保的议案》，同意公司担保下属子公司向相关银行申请综合授信共计 14.08 亿元，用于 子公司融资业务，具体额度在不超过 14.08 亿元的金额上限内以银行授信为准，以上综合授信 的金额在一年内以银行授信为准。《关于同意子公司 2026 年向相关银行申请综合授信额度并为 其提供担保的公告》详见公司指定信息披露媒体《证券时报》《中国证券报》《证券日报》和 巨潮资讯网（www.cninfo.com.cn）。 二、担保事项进展情况 近日公司与上海浦东发展银行股份有限公司海口分行签署了《最高额保证合同》 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2026-004 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理到期收回的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、现金管理到期收回情况 一心为民 全心服务 | | 式)(昆明分 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 行) 广发银 ...

Core Viewpoint - Yixin Tang (002727.SZ) has not yet won bids or made sales for EEG and other brain treatment devices, indicating a current focus on digital transformation and operational improvements [1] Group 1: Company Strategy - The company is undergoing a digital transformation phase aimed at enhancing store operations and optimizing the supply chain [1] - Yixin Tang is building a health management ecosystem to support its strategic initiatives [1] Group 2: Market Positioning - The company is leveraging local policy advantages in Hainan to accelerate the introduction and sales of innovative drugs [1]

Core Viewpoint - YXTT's stock price has shown a modest increase of 6.45% year-to-date, with a recent uptick of 2.16% on January 13, reflecting ongoing investor interest despite a slight decline in revenue and profit for the year [1][2]. Group 1: Stock Performance - As of January 13, YXTT's stock price reached 13.69 CNY per share, with a trading volume of 1.03 billion CNY and a turnover rate of 1.93%, resulting in a total market capitalization of 80.17 billion CNY [1]. - Year-to-date, YXTT's stock has increased by 6.45%, with a 3.87% rise over the last five trading days and a 9.00% increase over the last 20 days, although it has seen a 1.23% decline over the past 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, YXTT reported a revenue of 13.001 billion CNY, representing a year-on-year decrease of 4.33%, while the net profit attributable to shareholders was 269 million CNY, down 8.17% year-on-year [2]. - Since its A-share listing, YXTT has distributed a total of 2.023 billion CNY in dividends, with 764 million CNY distributed over the past three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, YXTT had 37,500 shareholders, an increase of 10.53% from the previous period, with an average of 10,596 circulating shares per shareholder, down 9.53% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 22.3144 million shares, an increase of 3.74 million shares from the previous period, and several new institutional investors have entered the top ten list [3].

Group 1 - The company has approved the use of up to RMB 2.5 billion of temporarily idle self-owned funds for cash management, which includes investments in fixed-income or capital-protected financial products, large deposits, and time deposits [1] - The company has signed contracts with Guangfa Bank and Huaxia Bank for structured deposit products as part of its cash management strategy [2] - The cash management investments are considered low-risk, but they are subject to market fluctuations and economic conditions, which may affect short-term returns [2][3] Group 2 - The cash management strategy aims to improve the efficiency of idle funds and generate investment returns, ultimately enhancing the company's overall performance and shareholder value [4] - The company emphasizes prudent investment principles to ensure the safety of funds, stating that cash management will not interfere with normal business operations or the execution of investment projects [4] - The company will conduct internal audits and monitoring of cash management investments to mitigate risks and ensure compliance with relevant regulations [3][4]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2026-003 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、现金管理到期收回情况 根据 2024 年年度股东会决议，公司与相关银行签署合同，使用部分暂时闲置自有资金进 行现金管理，现部分产品到期收回，基本情况如下： | 签约银行 名称 | 产品名称 | 认购金额 （万元） | ...

Core Viewpoint - YXTT's stock performance shows a slight increase of 0.61% on January 9, with a trading volume of 145 million yuan, indicating a stable market interest in the company [1] Financing Summary - On January 9, YXTT had a financing buy-in amount of 16.44 million yuan and a financing repayment of 14.24 million yuan, resulting in a net financing buy of 2.20 million yuan [1] - As of January 9, the total financing and margin trading balance for YXTT is 266 million yuan, with the financing balance accounting for 3.40% of the circulating market value, which is above the 80th percentile of the past year [1] - In terms of margin trading, YXTT repaid 2,400 shares on January 9, with no shares sold, and the margin balance is 1.15 million yuan, also exceeding the 80th percentile of the past year [1] Business Performance - As of September 30, YXTT reported a total revenue of 13 billion yuan for the first nine months of 2025, reflecting a year-on-year decrease of 4.33%, while the net profit attributable to shareholders was 269 million yuan, down 8.17% year-on-year [2] - Since its A-share listing, YXTT has distributed a total of 2.02 billion yuan in dividends, with 764 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, YXTT has 37,500 shareholders, an increase of 10.53% from the previous period, with an average of 10,596 circulating shares per shareholder, down 9.53% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 22.31 million shares, an increase of 3.74 million shares from the previous period [3] - New institutional shareholders include several funds, such as Xingquan Trend Investment Mixed Fund and Rongtong Health Industry Flexible Allocation Mixed Fund, indicating growing institutional interest in YXTT [3]

格隆汇1月8日丨一心堂(002727.SZ)在投资者互动平台表示，中药产业是公司主要发展的产业之一，公 司目前设立有云南鸿翔中药科技有限公司、鸿翔中药科技有限责任公司、云中药业有限公司等公司专注 于中药研究、种苗培育、中药材料收储、饮片加工、配方颗粒生产业务。其中公司全资子公司云中药业 有小范围的试种植。 ...

Group 1 - The core focus of the company is the traditional Chinese medicine industry, which is one of its main development areas [1] - The company has established several subsidiaries, including Yunnan Hongxiang Traditional Chinese Medicine Technology Co., Ltd., Hongxiang Traditional Chinese Medicine Technology Limited Liability Company, and Yunzhen Pharmaceutical Co., Ltd., which specialize in research, seedling cultivation, material storage, processing, and production of traditional Chinese medicine [1] - The wholly-owned subsidiary Yunzhen Pharmaceutical has initiated a small-scale trial planting [1]